Market Overview

UPDATE: Allergan Upgraded by Citigroup on Strong Fundamentals

Related AGN
Report: Actavis, Sanofi To Bid On Over-The-Counter Drug Maker
IBM's Report Weighs On The Dow, Apple Helps Boost The Nasdaq, S&P 500 Extends Winning Streak
Deal Frenzy: 2014 Sees Record M&A Volume (Fox Business)

Tuesday morning rating updates include an upgrade from Citigroup analyst Liav Abraham, boosting Allergen (NYSE: AGN) from Neutral to Buy, with a price rating of $130 from $95.

Citigroup is sold on Allergan's long-term growth with strong balance sheet and cash flow to back up their rating change. The report notes, "Following the recent removal of the Restasis and Lumigan overhangs, the fundamental risk-reward profile of AGN has shifted, in our view, with the stock offering the most attractive organic growth profile amongst the peer group, along with significant balance sheet optionality."

AGN is currently trading up around the $114 mark after closing Monday at $112.26.

Latest Ratings for AGN

DateFirmActionFromTo
Oct 2014CitigroupMaintainsBuy
Oct 2014Deutsche BankInitiates Coverage onBuy
Sep 2014ISI GroupInitiates Coverage onBuy

View More Analyst Ratings for AGN
View the Latest Analyst Ratings

Posted-In: Citigroup Liav AbrahamUpgrades Price Target Analyst Ratings

 

Related Articles (AGN)

Around the Web, We're Loving...

Get Benzinga's Newsletters